Author

Onsay Lau

Observed names: On S. Lau, On Say Lau

Institution: Johnson & Johnson (United States)

Observed institutions: Johnson & Johnson (United States), Janssen Research & Development (United States)

OpenAlex ID: A5083582020

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

2024 · Diana Cortes-Selva, Tatiana Perova, et al. · Blood · 67

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

2022 · Diana Cortes-Selva, Tineke Casneuf, et al. · Blood · 47

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

2023 · Deeksha Vishwamitra, Sheri Skerget, et al. · Blood · 15

Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma

2023 · Deeksha Vishwamitra, Sheri Skerget, et al. · Blood · 11

Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up

2023 · Rocio Montes de Oca, Junchen Gu, et al. · Blood · 9

Cardioprotective Effects of Mitochondrial-Targeted Antioxidants in Myocardial Ischemia/Reperfusion (I/R) Injury

2013 · Regina Ondrasik, Qian Chen, et al. · 4

Longitudinal mechanisms of response, resistance and relapse to teclistamab in multiple myeloma: results from MajesTEC-1

2026 · Deeksha Vishwamitra, Sheri Skerget, et al. · Haematologica · 1

Cardioprotective Effects of Cell Permeable NADPH Oxidase Inhibitors in Myocardial Ischemia/Reperfusion (I/R) Injury

2013 · Issachar Devine, Qian Chen, et al.

Works count: 8

Citation count: 154

H-index: 5

I10-index: 4